Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer cachexia and weight loss prior to CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin SM, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I Dr, Schöder H, Bedmutha A, Boardman AP, Shah GL, Scordo M, Perales MA, Salles GA, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: landego i dr. Blood Adv. 2024 Oct 29:bloodadvances.2024014555. doi: 10.1182/bloodadvances.2024014555. Online ahead of print. Blood Adv. 2024. PMID: 39471490
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G, Fregonese B, Wills B, Bedmutha A, Alarcon Tomas A, Parascondola A, Saldia A, Landego I, Hajj C, Boardman AP, Dahi PB, Ghosh A, Giralt S, Lin RJ, Park J, Scordo M, Salles G, Yahalom J, Palomba ML, Schöder H, Perales MA, Shouval R, Imber BS. Hubbeling H, et al. Among authors: landego i. Clin Cancer Res. 2024 Nov 15;30(22):5083-5093. doi: 10.1158/1078-0432.CCR-24-0830. Clin Cancer Res. 2024. PMID: 39259292
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, Raj SS, Giralt SA, Palomba ML, Dahi PB, Walji M, Salles G, Nath K, Geyer MB, Park JH, Fein JA, Kosmidou I, Shah GL, Liu JE, Perales MA, Mahmood SS. Shouval R, et al. Among authors: landego i. Br J Haematol. 2024 Sep;205(3):978-989. doi: 10.1111/bjh.19497. Epub 2024 May 12. Br J Haematol. 2024. PMID: 38735683
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.
Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Schöder H. Leithner D, et al. Among authors: landego i. J Hematol Oncol. 2024 Apr 23;17(1):21. doi: 10.1186/s13045-024-01540-x. J Hematol Oncol. 2024. PMID: 38649972 Free PMC article.
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
Gong IY, Aminilari M, Landego I, Hueniken K, Zhou Q, Kuruvilla J, Hodgson DC. Gong IY, et al. Among authors: landego i. Leuk Lymphoma. 2023 Oct;64(10):1643-1654. doi: 10.1080/10428194.2023.2234528. Epub 2023 Aug 7. Leuk Lymphoma. 2023. PMID: 37548344
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
Yang J, Yang L, Tordon B, Bucher O, Nugent Z, Landego I, Bourrier N, Uminski K, Brown K, Squires M, Marshall AJ, Katyal S, Mahmud S, Decker K, Geirnaert M, Dawe DE, Gibson SB, Johnston JB, Banerji V. Yang J, et al. Among authors: landego i. Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472. Curr Oncol. 2023. PMID: 37504332 Free PMC article.
Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N, Landego I, Bucher O, Squires M, Streu E, Hibbert I, Whiteside T, Gibson SB, Geirnaert M, Johnston JB, Dawe DE, Banerji V. Bourrier N, et al. Among authors: landego i. BMC Cancer. 2022 Feb 6;22(1):148. doi: 10.1186/s12885-022-09256-2. BMC Cancer. 2022. PMID: 35123433 Free PMC article.
13 results